APPX_OUT_1 [2025-04-28 07:23:40 -0400] 1978 Bytes | 482 tokens | Cum: 482 tkns (6.02% of 8k)
==========================================================================

We need a winner today and it's already 7:23 AM on Mon Apr 28, 2025 ... So let's find out if Tradr 2X Long (APPX) is going up or if it's going nowhere fast. So, I pulled together a bunch of data for you to look over real fast. It's at $26.73 up from $23.70. Is there something here we can get excited about? Help me analyze.

--- COMPANY PROFILE ---
Company: Tradr 2X Long (APPX)
IPO: IPO date unknown
Exchange: XNAS

Here’s a list of headlines for Tradr 2X Long:

Apr-25-25 06:45AM - Tradr Launches Leveraged ETFs on APP and QBTS

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Tradr 2X Long (APPX).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

APPX_OUT_3 [2025-04-28 07:23:41 -0400] 508 Bytes | 137 tokens | Cum: 621 tkns (7.76% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-25T10:45:00Z - Tradr Launches Leveraged ETFs on APP and QBTS - AppLovin (NASDAQ:APP), D-Wave Quantum (NYSE:QBTS)...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

APPX_OUT_5 [2025-04-28 07:23:41 -0400] 1181 Bytes | 340 tokens | Cum: 963 tkns (12.04% of 8k)
==========================================================================

Showing A1 (chunk 1 of 7): A1:
**Tradr Launches Leveraged ETFs on APP and QBTS - AppLovin (NASDAQ:APP), D-Wave Quantum (NYSE:QBTS)**Date: 2025-04-25Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/pressreleases/25/04/n45003837/tradr-launches-leveraged-etfs-on-app-and-qbtsAPPX and QBTX Offer 2X Daily Exposure to High-Growth Companies

NEW YORK, April 25, 2025 /PRNewswire/ -- Tradr ETFs, a provider of ETFs designed for sophisticated investors and professional traders, today announced the launch of two new single stock leveraged ETFs: APPX and QBTX. These funds aim to deliver twice (200%) the daily performance of the common stock of innovative companies with exposure to advertising technology and quantum computing. The new ETFs include:

Tradr 2X Long APP Daily ETF APPX - tracks AppLovin Corp. (APP)

Tradr 2X Long QBTS Daily ETF QBTX - tracks D-Wave Quantum Systems

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

APPX_OUT_7 [2025-04-28 07:23:42 -0400] 1181 Bytes | 279 tokens | Cum: 1244 tkns (15.55% of 8k)
==========================================================================

Showing A1 (chunk 2 of 7): , Inc. (QBTS)

Traders who are bullish on AppLovin or D-Wave can utilize Tradr ETFs' new funds to take advantage of swings in their daily stock price without using a margin account. The ETFs mark the first-ever leveraged products tied to the underlying stocks, further cementing Tradr's distinction as a pioneer in the single-stock ETF space. In 2022, Tradr ETFs became the first issuer to launch leveraged ETFs on single stocks, starting with TSLQ for Tesla and NVDS for Nvidia.

"Our goal is to provide traders with the sharpest tools available so they can capitalize on the exciting narratives represented by ad tech and quantum computing," said Matt Markiewicz, Head of Product and Capital Markets at Tradr ETFs. "Both of these underlying stocks offer a unique combination of volatility, liquidity and a compelling growth story. In today's fast-moving equity market, we believe high-conviction tr

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

APPX_OUT_9 [2025-04-28 07:23:42 -0400] 1181 Bytes | 251 tokens | Cum: 1497 tkns (18.71% of 8k)
==========================================================================

Showing A1 (chunk 3 of 7): aders looking for transparency and simplicity will appreciate Tradr's distinctive leveraged ETFs."

APPX and QBTX can be accessed through brokerage accounts and allow investors to avoid the hassle of using margin and the complexity of options trading. With these launches, Tradr's lineup grows to nine leveraged ETFs. The firm continues its mission of providing sophisticated investors with innovative trading tools that enhance their ability to express market views with precision and efficiency.

For detailed information on Tradr ETFs and the significant risks involved with leveraged ETFs, please visit www.tradretfs.com.

About Tradr ETFs

Tradr ETFs are designed for sophisticated investors and professional traders who are looking to express high conviction investment views. The strategies include leveraged and inverse ETFs that seek short or long exposure to actively traded stocks and ETFs

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

APPX_OUT_11 [2025-04-28 07:23:43 -0400] 1111 Bytes | 313 tokens | Cum: 1812 tkns (22.65% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2008-08-04 10-Q ITEM 1. FIN STATEMENTS APP Pharmaceuticals, Inc.

Condensed Cons Balance Sheets

(Unaudited)

June 30, 2008 December 31, 2007 (in thousands, except share data) (Unaudited) (Note 1) Assets

Curr assets:

Cash and cash equiv

$ 73,890 $ 31,788 Acco...

S2 - 2008-08-01 8-K ITEM 2.02 Results of Oper and Fin Cond. On August 1, 2008, APP Pharmaceuticals, Inc. (the Company) issued a press release announcing its preliminary financial results for the three and six months ended June 20, 2008. A copy of the press release is furnished (but ...

S3 - 2008-07-07 8-K ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT

On July 6, 2008, APP Pharmaceuticals, Inc., a Delaware corporation (APP), Fresenius SE, a societas europaea organized under the laws of Germany (FSE), Fresenius Kabi Pharmaceuticals Holding, LLC, a Delaware limited liability ...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

APPX_OUT_13 [2025-04-28 07:23:44 -0400] 1181 Bytes | 347 tokens | Cum: 2161 tkns (27.01% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
ITEM 1. FINANCIAL STATEMENTS APP Pharmaceuticals, Inc.

Condensed Consolidated Balance Sheets

(Unaudited)

June 30, 2008 December 31, 2007 (in thousands, except share data) (Unaudited) (Note 1) Assets

Current assets:

Cash and cash equivalents

$ 73,890 $ 31,788 Accounts receivable, net

73,387 85,209 Inventories

169,680 149,191 Prepaid expenses and other current assets

13,792 13,531 Current receivables from related parties

6,996 Income taxes receivable

1,471 Deferred income taxes

16,020 17,109 Total current assets

348,240 303,824 Property, plant and equipment, net

131,476 132,528 Intangible assets, net

447,949 463,154 Goodwill

160,239 160,239 Deferred financing costs and other non-current assets, net

17,159 17,842 Total assets

$ 1,105,063 $ 1,077,587 Liabilities and stockholders deficit

Current liabilities:

Accounts payable

$ 3

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

APPX_OUT_15 [2025-04-28 07:23:45 -0400] 1181 Bytes | 347 tokens | Cum: 2510 tkns (31.37% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): 8,285 $ 36,502 Accrued liabilities

35,952 45,595 Current payables from related parties

1,024 Fair value of interest rate swap

2,084 Current portion of long-term debt

11,250 5,000 Total current liabilities

88,595 87,097 Long-term debt

986,250 995,000 Deferred income taxes, non-current

67,064 71,011 Other non-current liabilities

4,841 4,250 Total liabilities

1,146,750 1,157,358 Stockholders deficit:

Common stock - $0.001 par value; 350,000,000 shares authorized; 160,432,781 and 160,069,196 shares issued and outstanding in 2008 and 2007

160 160 Additional paid-in capital

(89,129 ) (96,357 ) Retained earnings

46,764 13,715 Accumulated other comprehensive income

518 2,711 Total stockholders deficit

(41,687 ) (79,771 ) Total liabilities and stockholders deficit

$ 1,105,063 $ 1,077,587 See accompanying notes to condensed consolidated financial sta

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

APPX_OUT_17 [2025-04-28 07:23:45 -0400] 1181 Bytes | 382 tokens | Cum: 2894 tkns (36.18% of 8k)
==========================================================================

Showing S1 (chunk 3 of 6): tements

APP Pharmaceuticals, Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

Three Months Ended June 30, Six Months Ended June 30, 2008 2007 2008 2007 (in thousands, except per share data) (in thousands, except per share data) Net revenue

$ 197,918 $ 159,327 $ 345,997 $ 299,595 Cost of sales

103,771 79,177 181,788 154,008 Gross profit

94,147 80,150 164,209 145,587 Operating expenses:

Research and development

13,833 12,678 26,163 22,642 Selling, general and administrative

21,173 22,678 42,193 44,739 Amortization of merger related intangibles

3,857 3,856 7,713 7,712 Separation related costs

1,212 352 1,603 704 Merger related costs

805 805 Total operating expenses

40,880 39,564 78,477 75,797 Income from operations

53,267 40,586 85,732 69,790 Interest income and other

514 663 1,493 929 Interest expense

(14,041 ) (5,040 ) (30,75

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

APPX_OUT_19 [2025-04-28 07:23:46 -0400] 1181 Bytes | 378 tokens | Cum: 3274 tkns (40.92% of 8k)
==========================================================================

Showing S1 (chunk 4 of 6): 7 ) (8,916 ) Income from continuing operations before income taxes

39,740 36,209 56,468 61,803 Provision for income taxes from continuing operations

15,848 13,417 23,419 25,394 Income from continuing operations

23,892 22,792 33,049 36,409 Net income (loss) from discontinued operations, net of taxes

294 (2,208 ) Net income

$ 23,892 $ 23,086 $ 33,049 $ 34,201 Basic net income (loss) per common share:

Continuing operations

$ 0.15 $ 0.14 $ 0.21 $ 0.23 Discontinued operations

(0.02 ) Net income per basic common share

$ 0.15 $ 0.14 $ 0.21 $ 0.21 Diluted net income (loss) per common share:

Continuing operations

$ 0.15 $ 0.14 $ 0.20 $ 0.23 Discontinued operations

(0.02 ) Net income per diluted common share

$ 0.15 $ 0.14 $ 0.20 $ 0.21 The composition of stock-based compensation included above is as follows:

Cost of sales

$ 196 $ 766 $ 961 $ 1,520 Resea

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

APPX_OUT_21 [2025-04-28 07:23:47 -0400] 1181 Bytes | 346 tokens | Cum: 3622 tkns (45.27% of 8k)
==========================================================================

Showing S1 (chunk 5 of 6): rch and development

65 138 350 292 Selling, general and administrative

1,237 2,543 3,202 5,667 Discontinued operations

3,904 9,592 $ 1,498 $ 7,351 $ 4,513 $ 17,071 See notes to condensed consolidated financial statements.

APP Pharmaceuticals, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

June 30, 2008 June 30, 2007 (six months ended, in 000s) Cash flows from operating activities:

Net income from continuing operations

$ 33,049 $ 36,409 Net loss from discontinued operations, net of taxes

(2,208 ) Net income

33,049 34,201 Adjustments to reconcile net income to net cash provided by (used in) operating activities:

Depreciation

9,259 13,258 Amortization

1,213 394 Amortization of product rights

8,220 8,220 Amortization of merger related intangibles

7,713 27,018 Stock-based compensation

4,513 17,071 Loss on disposal of property,

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

APPX_OUT_23 [2025-04-28 07:23:47 -0400] 790 Bytes | 216 tokens | Cum: 3840 tkns (48.00% of 8k)
==========================================================================

Showing S1 (chunk 6 of 6): plant and equipment

35 418 Excess tax benefit from stock-based compensation

(493 ) (518 ) Stock option grants/forfeitures

(328 ) Deferred income taxes

(2,055 ) (4,580 ) Equity in net income of Drug Source Company, LLC, net of dividends received

(1,908 ) Changes in operating assets and liabilities:

Accounts receivable, net

11,822 (14,436 ) Inventories

(20,489 ) (13,327 ) Prepaid expenses and other current assets

73 2,001 Receivables from related parties

8,020 Deferred re...

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

APPX_OUT_25 [2025-04-28 07:23:53 -0400] 3835 Bytes | 928 tokens | Cum: 4770 tkns (59.62% of 8k)
==========================================================================

This is our set of metrics for Tradr 2X Long.
Please analyze the numbers.

+--------------------+----------------+-----------------+-----------------------+
| Volume: 29,070 | ATR (14): 1.95 | Perf Week: - | Market Cap: |
+--------------------+----------------+-----------------+-----------------------+
| Avg Volume: 29.07K | SMA20: 0.00% | Perf Month: - | Shs Outstand: |
+--------------------+----------------+-----------------+-----------------------+
| Rel Volume: - | SMA50: 0.00% | Perf Quarter: - | Option/Short: No / No |
+--------------------+----------------+-----------------+-----------------------+
| RSI (14): - | SMA200: 0.00% | Index: - | Beta: - |
+--------------------+----------------+-----------------+-----------------------+

The next section covers any insider trading by Tradr 2X Long officers or majority shareholders (if available).

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: N/A
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 26.7323
Average Volume: 29106.0
30-Day High: 26.7323
30-Day Low: 26.7323
No detailed financial data available.
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Tradr 2X Long (APPX).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Tradr 2X Long.

2) MARKET_SCORE[]
This conversation was initiated because APPX is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for APPX.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, APPX could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect APPX to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Tradr 2X Long.

11) ETHICAL_RATING[]
Rate Tradr 2X Long’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Tradr 2X Long.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

APPX_IN_27 [2025-04-28 07:23:53 -0400] 126 Bytes | 29 tokens | Cum: 5001 tkns (62.51% of 8k)
==========================================================================

====================================
[2025-04-28 07:23:53] # Analysis Completed
Elapsed Time: 13.76 seconds